Misplaced Pages

Leflutrozole

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Chemical compound Pharmaceutical compound
Leflutrozole
Clinical data
Other namesBGS-649; CGP-47645
Routes of
administration		By mouth
Identifiers
IUPAC name
  • 4-benzonitrile
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H10FN5
Molar mass303.300 g·mol
3D model (JSmol)
SMILES
  • C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)(N3C=NC=N3)F
InChI
  • InChI=1S/C17H10FN5/c18-17(23-12-21-11-22-23,15-5-1-13(9-19)2-6-15)16-7-3-14(10-20)4-8-16/h1-8,11-12H
  • Key:PZDLRBUQYWMNBR-UHFFFAOYSA-N

Leflutrozole (developmental code names BGS-649, CGP-47645) is an aromatase inhibitor which is under development by Mereo BioPharma and Novartis for the treatment of hypogonadism in men. It was also under investigation for the treatment of endometriosis, but development for this indication was discontinued. As of December 2017, leflutrozole is in phase II clinical trials for hypogonadism.

See also

References

  1. ^ "Leflutrozole - Mereo BioPharma - AdisInsight".

External links


Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Misplaced Pages by expanding it.

Categories: